Search

Blog

We constantly analyse the legislation and regulatory information related to a specific medicine in order to appraise the context in which the company operates

We put all our knowledge into play to anticipate risks and seize every opportunity, but above all to understand the rules of the game and display our creativity with them. We spread material and information proceeding from our investigation into medicines governance and regulatory science. In fact, we deem it necessary to be aware of the complexity of the results of research, regulation and drug policy in order to be able to work in a cultural ecosystem aiming both at promoting research outcomes that are useful to patients and at encouraging politicians to protect people’s health. The wider the knowledge of each interest group, the greater their ability to interact and achieve transparency of procedures and health protection.

  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
All
  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value

New AIFA special: CSE and reorganisation

The series of Nomos and Pharma Value specials regarding the governance of the Medicine and its Agency continues. After the seven extensions ...
Read more "

LEA 2024 Commission

The National Commission for Updating the Essential Levels of Care (LEA) was renewed by Ministerial Decree of 18/03/2024. The President of the Commission ...
Read more "

Happy Easter from #TeamPharmaValue

Our Easter greeting this year is multi-voiced. Each person in the team wanted to share their thoughts on Easter, ...
Read more "

Pharma Value_1 year from SRL

A year has already passed since 17 February 2023, when, defying superstition and low immune defences, Pharma Value decided to grow, ...
Read more "

Just be patient

On 14 February 2024 in Rome, at the Capranichetta Hall of the Hotel Nazionale, the presentation of 'Basta essere Pazienti', a campaign by the ...
Read more "

New AIFA Special Update: CSE and REORGANISATION

Update 1 March 2024 Below is the updated document with appointments and update timeline to 1 March 2024. Original text Pharma Value has ...
Read more "
negotiating orphan drugs

The Orphan Drug Comparator: a survey to identify challenges in price negotiations with AIFA

In collaboration with Rarelab, we launched a survey with the aim of assessing the actual impact of the use of comparators in the negotiation of orphan drugs, ...
Read more "
Drug Agency

Interministerial Decree for new AIFA regulation published

Yesterday, 15 January 2024, the Ministerial Decree for the reform of AIFA was published in the OJ. It will enter into force on 30 January 2024. ...
Read more "

FDA vs EMA - Comparison of marketing authorisations issued in 2023

Pharma Value has developed a paper comparing marketing authorisations issued by the FDA and EMA in 2023. The objective of the analysis is to ...
Read more "
en_GB